Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONM-100 in solid tumors
NCT03735680Phase 2Completed
- Sponsor
- OncoNano Medicine
- Start
- Aug 2019
- Primary completion
- Oct 2021
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pegsitacianine in breast cancer, head and neck squamous cell carcinoma (HNSCC), colorectal cancer (CRC), prostate cancer (PCa), ovarian cancer, sponsored by OncoNano Medicine. Started Aug 2019; status: completed.
02
Drugs
pegsitacianine
03
Conditions
breast cancerhead and neck squamous cell carcinoma (HNSCC)colorectal cancer (CRC)prostate cancer (PCa)ovarian cancer
Beyond the preview
Go deeper on NCT03735680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03735680.